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Abstract
Hepatic pseudolymphoma (HPL) and primary hepatic marginal zone B cell lymphoma of mucosa-associated
lymphoid tissue (MALT lymphoma) are rare diseases and the differential diagnosis between these two entities is
sometimes difficult. We herein report a 56-year-old Japanese woman who was pointed out to have a space
occupying lesion in the left lateral segment of the liver. Hepatitis viral-associated antigen/antibody was negative
and liver function tests including lactic dehydrogenase, peripheral blood count, tumor markers and soluble
interleukin-2 receptor were all within normal limit. Imaging study using computed tomography and magnetic
resonance imaging were not typical for hepatocellular carcinoma, cholangiocarcinoma, or other metastatic cancer.
Fluorodeoxyglucose-positron emission tomography examination integrated with computed tomography scanning
showed high standardized uptake value in the solitary lesion in the liver. Under a diagnosis of primary liver
neoplasm, laparoscopic-assisted lateral segmentectomy was performed. Liver tumor of maximal 1.0 cm in diameter
was consisted of aggregation of lymphocytes of predominantly B-cell, containing multiple lymphocyte follicles
positive for CD10 and bcl-2, consistent with a diagnosis of HPL rather than MALT lymphoma, although a definitive
differentiation was pending. The background liver showed non-alcoholic fatty liver disease/early non-alcoholic
steatohepatitis. The patient is currently doing well with no sign of relapse 13 months after the surgery. Since the
accurate diagnosis is difficult, laparoscopic approach would provide a reasonable procedure of diagnostic and
therapeutic advantage with minimal invasiveness for patients. Considering that the real nature of this entity
remains unclear, vigilant follow-up of patient is essential.
Background
A primary hepatic lymphoma (PHL) is defined as
lymphoma localized and limited in the liver [1], not the
secondary involvement of high- or intermediate grade
non-Hodgkin’s lymphoma, and accounts for less than
1% of all extranodal lymphomas [2]. Among them, a
primary hepatic low-grade marginal zone B cell lym-
phoma of mucosa-associated lymphoid tissue (MALT
lymphoma) is extremely rare.
On the other hand, hepatic pseudolymphoma (HPL),
also termed as reactive lymphoid hyperplasia, or nodular
lymphoid lesion, is extremely rare disease and character-
ized by the proliferation of non-neoplastic, polyclonal
lymphocytes forming follicles with an active germinal
center [3], and most importantly, is mimicking clinico-
pathologically to low grade lymphoma including MALT
lymphoma.
The etiology, pathogenesis and clinical implications of
these two diseases remain unknown to a large extent.
Reported underlying liver diseases include chronic viral
hepatitis, autoimmune liver diseases, etc [4].
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Since clinical diagnosis is often difficult especially at
its earlier stage, surgical resection appears a mainstay
for diagnostic/therapeutic purpose.
We herein present a laparoscopically operated case of
hepatic pseudolymphoma which was difficult to differen-
tially diagnose from primary hepatic MALT lymphoma,
and discuss the clinicopathological features and clinical
implications of these two disease entity.
Case presentation
In April 2009, a 56-year-old Japanese woman was
pointed out to have a space occupying lesion in the lat-
eral segment of the liver on abdominal ultrasonography
during health examination. Her social and family history
was noncontributory and she had a previous medical
history of appendectomy for acute appendicitis and
laparoscopic cholecystectomy for cholecystolithiasis. She
showed no abnormal physical findings, including lym-
phadenopathy and hepatosplenomegaly.
Laboratory findings of blood examination were almost
normal, including blood cell counts and differentiation,
serochemical tests including liver enzymes and lactate
dehydrogenase (LDH), hepatitis viral associated markers
including hepatitis B virus surface antigen (HBsAg), hepa-
titis B virus core antibody (HBcAb) and hepatitis C virus
(HCV) antibody. Also, tumor markers including carci-
noembryonic antigen and carbohydrate antigen 19-9,
alpha-fetoprotein (AFP), fucosylated AFP (L3-AFP), pro-
tein induced by vitamin-K absence or antagonist II (des-
gamma carboxy prothrombin, PIVKA-II), and soluble
interleukin 2 (s-IL2) receptor were within normal limits.
Abdominal ultrasonography showed 15-mm-diameter
hypoechoic in segment 3 in the liver, and on enhance-
ment study, it showed slight enhancement of ring-like in
the peripheral but not in the entire tumor, the center of
which being minimally enhanced, which indicated meta-
static tumor rather than hepatocellular carcinoma (HCC).
On abdominal computed tomography (CT) scan
(Figure 1), 15-mm-diameter low density area was
demonstrated before contrast material injection, which
was enhanced in early arterial phase and subsequently
washed out in the late phase after contrast material
injection, not incompatible with HCC. Other organs
including regional or para-aortic lymph nodes showed
no abnormal finding.
On magnetic resonance imaging (MRI, Figure 2), the
hepatic tumor was low signal intensity in T1-weighted
imaging and slight high signal intensity in T2-weighted
imaging, and low intensity in hepatobiliary phase
20 minutes after injection of gadolinium ethoxybenzyl
diethylenetriamine pentaacetic acid (Gd-EOB-DTPA,
Primovist, Bayer Schering Pharma), and on dynamic
Gd-EOB-DTPA MRI protocol not clearly visualized dur-
ing arterial dominant phase and slight ring-like
enhancement persisted, indicating hypovascular tumor,
such as cholangiocarcinoma or liver metastasis.
On gastric fiberscope examination, atrophic gastritis
was noted without evidence of MALT lymphoma. She
had previously received eradication treatment for Heli-
cobacter pylori. Colonoscopy examination found no
other lesions.
In a fluorodeoxyglucose-positron emission tomogra-
phy examination integrated with computed tomography
scanning (FDG-PET CT, Figure 3), the tumor was
revealed to have a high standardized uptake value (SUV-
max: 3.6) for FDG. No other site showed FDG uptake,
suggesting that liver tumor is not secondary from malig-
nant lesions of other organs.
Abdominal angiography revealed small tumor stain in
the tributaries of A2 during arterial phase; hence trans-
catheter arterial infusion of epirubicin and lipiodol was
performed under the diagnosis of small HCC.
Percutaneous needle biopsy was performed, but failed to
provide with definitive diagnosis regarding the tumor
partly due to inappropriate material obtained because of
the size of the targeted tumor, except for chronic hepatitis
of minimal grade activity and fibrosis (A1/F1, according to
the New Inuyama Classification [5], and hepatocyte bal-
looning with fatty degeneration being noted.
In November 2009, under a clinical diagnosis of pri-
mary malignant liver tumor, laparoscopic-assisted lateral
segmentectomy was performed.
Figure 1 Unenhanced CT scan showed low density area of 1
cm in diameter in the segment 3 of the liver (arrow). Contrast-
enhanced CT scan during arterial phase showed minimally
peripheral ring enhancement. No lymphadenopathy or
hepatosplenomegaly was observed.
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On macroscopic examination, there was a grey-white
solid tumor, measuring 1.0 cm in largest diameter
(Figure 4). The tumor was completely excised. On
microscopic examination, the tumor in the liver was
composed of dense lymphocytic infiltration including
multiple lymphoid follicles with germinal centers
(Figure 5A). The interfollicular areas were expanded and
filled with small to medium-sized lymphocytes with pale
cytoplasm and cellular atypia (Figure 5B, C), most of
which were positive for CD20 and bcl-2 (Figure 5D, E),
and negative for CD5 and CD10. Lymphoepithelial
lesions with bile duct epithelium destruction by lym-
phoid tumor cells were noticed (Figure 5F). At the edge
of the nodule, lymphocytic infiltration extended into
perinodular portal tracts (Figure 5G). Bile ducts were
observed at the periphery of the nodule (Figure 5H). Ki-
67 index of those lymphoid cells was 25%. Taken
together, these findings were consistent with diagnosis
of both extranodal marginal zone B-cell lymphoma and
Figure 2 Magnetic resonance imaging (MRI), the hepatic tumor (arrow) was low signal intensity in T1-weighted image (A) and slight
high signal intensity in T2-weighted image (B), and low signal intensity in hepatobiliary phase after Gd-EOB-DTPA injection, and on
dynamic Gd-EOB-DTPA MRI protocol not clearly visualized during arterial dominant phase with slight ring-like enhancement
persisting, indicating hypovascular tumor, such as cholangiocarcinoma or liver metastasis.
Figure 3 FDG-PET CT demonstrated the tumor had a high
standardized uptake value (SUVmax: 3.6) for FDG. No other site
showed FDG uptake, suggesting that liver tumor is not secondary
from malignant lesions of other organs.
Figure 4 Resected specimen: section of the liver and 12 × 10
mm, well-defined, light-tan, firm, solid nodule (arrow).
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Figure 5 Microscopic appearance of the lesion. (A) Low-power view of the tumor showing dense lymphocytic infiltration with lymph follicles
(hematoxylin and eosin, original magnification ×4). (B) Interfollicular areas are infiltrated with small to intermediate-sized lymphocytes with pale
cytoplasm, which are characteristic features of hepatic pseudolymphoma as well as marginal zone B-cell lymphoma (hematoxylin and eosin,
original magnification ×40). (C) Intermediate-sized atypical lymphocytes are observed (hematoxylin and eosin, original magnification ×40). (D)
Most of the lymphoid cells are positive for CD20. These cells are negative for CD5, which rules out other small B-cell non Hodgkin lymphomas,
including lymphocytic lymphoma and mantle cell lymphoma (original magnification ×4). (E) Bcl-2 expression in the mantle zones and the
interfollicular areas (original magnification ×4). (F) Lymphoepithelial lesions are observed at the bile ducts (hematoxylin and eosin, original
magnification ×40). (G) At the edge of the nodule, lymphocytic infiltration extends into perinodular portal tracts (hematoxylin and eosin, original
magnification ×10). (H) Bile ducts are observed at the periphery of the nodule (hematoxylin and eosin, original magnification ×10).
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non-neoplastic lesion mimicking MALT lymphoma
including HPL, reactive lymphoid hyperplasia, or nodu-
lar lymphoid lesion, but still insufficient to distinguish
these conditions. Polymerase chain reaction was per-
formed to detect monoclonal immunoglobulin heavy
chain (IGH) gene rearrangement in an attempt to differ-
entiate these two entities, but was unsuccessful due to
degradation of extracted DNA from the specimen, pre-
sumably partly because of deleterious effect on DNA
integrity by the previous local tumor ablation using
transcatheter arterial chemo-embolization. The back-
ground liver showed 30% macrovesicular steatosis with
scattered ballooned cells and perivenular fibrosis, sug-
gesting non-alcoholic fatty liver disease (NAFLD) or
early non-alcoholic steatohepatitis (NASH). No histolo-
gical finding suggested concomitant primary biliary cir-
rhosis (PBC) or viral hepatitis.
The postoperative course of this patient was unevent-
ful and she was discharged from the hospital on post-
operative day 8. Any adjuvant chemotherapy or
radiotherapy was not indicated, considering that the
tumor was confined in the liver with no extrahepatic
involvement, and she is currently doing well with no
sign of relapse 13 months after the surgery.
Discussion
Hepatic pseudolymphoma (HPL), also known as reactive
lymphoid hyperplasia, or nodular lymphoid lesion, is
extremely rare disease entity and so far 35 cases have
been reported worldwide [4,6-9] since the first report by
Sharifi et al [10]. Its pathogenesis and clinical implica-
tions have not been fully elucidated. According to the
recently proposed criteria by Zen et al, the present case
reported here would be diagnosed with HPL, although
not confirmed by molecular examination, such as detec-
tion of gene rearrangement.
Primary hepatic marginal zone B-cell lymphoma of the
mucosa-associated lymphoid tissue type (MALT lym-
phoma), also rare entity with only 48 cases being
reported in the worldwide literature [11-22] since the
first report by Isaacson et al [23], accounts for 1.6-3% of
PHL [24,25], is the most important differential diagnosis
from HPL.
The etiopathogenesis of HPL remains unclear,
although 27% of the patients had chronic liver diseases
including HBV- or HCV-related liver cirrhosis, and
moreover, 23% had autoimmune disorders, such as PBC,
in extrahepatic organs [26]. In terms of background dis-
orders, this figure is comparable with that of MALT
lymphoma, where half of the patients have chronic
inflammatory liver diseases including autoimmune disor-
ders [11,21,27,28]. The similarity would imply the com-
mon pathogenesis of these two conditions. In this
regard, several authors have proposed that chronic
persistent, prolonged immunogenic stimulation targeted
either to infectious agents, such as Helicobacter pylori
and HCV, and autoimmune diseases, such as PBC,
Hashimoto thyroiditis, and Sjögren syndrome, would
induce development of acquired MALT and subse-
quently MALT lymphoma [28], and/or HPL during this
process as well [29].
As a background liver condition associating with HPL,
in accordance with the case reported by Zen et al [26],
our case would suggest the possible role for NAFLD/
NASH as a pathogenesis in this entity through chronic
persistent inflammatory stimulation in the liver, though
via non-immunological pathway, yet further study is
required on this matter.
Clinical resemblance includes the age of patients
(mean age, 55.1 vs. 61.4 years old, HPL vs. MALT lym-
phoma), and tumor characteristics including the size
(size range, 0.5-5.5 vs. 2-7.7 cm, HPL vs. MALT lym-
phoma) and the number, where the majority of cases
had solitary tumor at presentation in both entities (81%
vs. 78%, HPL vs. MALT lymphoma). The single pro-
nounced difference would be the female preponderance
in HPL (86% vs. 51%, HPL vs. MALT lymphoma, 4,
16, 26).
The diagnosis of HPL, not to mention the preopera-
tive one, appears challenging. In fact, the case report by
Sato et al indicating the transformation of HPL into
lymphoma [30] would implicate the significance, as well
as difficulty, of differential diagnosis of these two condi-
tions. In our case, since the lack of molecular diagnosis
hampered the definitive diagnosis, there still remains
insufficiency in differential diagnosis from hepatic
MALT lymphoma [26]. Therefore, molecular analysis
should be routinely undertaken as the most potent diag-
nostic tool in such a controversial case. However, at the
same time, it should be noted that even a clonal IGH
rearrangement would not be a gold standard for a diag-
nosis of lymphoma, as suggested by Geyer et al. in the
setting of lower female genital tract, and therefore both
routine microscopic findings and detailed clinical infor-
mation remain paramount in establishing the correct
diagnosis [31]. In this context, the clinical course of this
patient on careful follow-up hereafter might elucidate
the essentials of this disorder.
Regarding the diagnostic significance of FDG-PET, no
report on HPL is currently available. In contrast, FDG-
PET has been reported in the recent two reports as a
useful and convenient modality for the diagnosis of
hepatic MALT lymphoma [21,22]. Considering the posi-
tive uptake of FDG seen in our case, however, this
examination would not be used solely to differentiate
the two conditions.
Natural history of HPL is yet delineated. Malignant
transformation of pseudolymphoma into true lymphoma
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has been reported in the various organs, such as lung,
stomach, and skin [32-34], but actual frequency have
not evaluated, since the majority of cases underwent
surgical resection under a suspicion for malignancy.
Regarding liver, since only one case report is available
[30], the possibility of transformation of HPL into hepa-
tic MALT lymphoma could not be determined. There-
fore, surgical removal is the treatment of choice for
these conditions [35]. Further accumulation of clinical
data is required to clarify this matter.
With respect to treatment strategy, reported cases
demonstrated that even MALT lymphoma has a favor-
able prognosis compared with other subtypes of PHL; the
former is usually limited to the liver and surgical resec-
tion cures the patient in most cases [36]. Also, when
diagnosis is confirmed after needle biopsy, non-resection
treatment procedures would be permitted, such as radio-
frequency ablation [37] instead of surgical resection.
Furthermore, in case of HPL, simple observation proved
to be practically enough since spontaneous diminution of
tumor size or even regression of tumor has been reported
[26,38], yet further accumulation of data is needed.
Regarding prognosis after treatment, since no recur-
rence of MALT lymphoma has been reported to date to
occur after adequate surgical resection or chemotherapy
treatments [21], even if the tumor is true neoplastic
lesion, as long as it remains low-grade malignancy, the
surgical outcome would be comparable with that for
HPL. However, it should be noted that there is a single
report of local recurrence after surgical resection, sug-
gesting the importance of close post-treatment follow-up
[39]. Considering the relatively short duration of observa-
tion period in the reported cases, vigilant follow-up of the
patients including our case would be required.
PHL and lymphoid lesions in general should be consid-
ered in the differential diagnosis of space occupying
lesions of the liver in the absence of elevated levels of
ordinary tumor markers including AFP and CEA [40]. In
addition, it is also important to distinguish HPL and
MALT lymphoma from others, particularly from more
aggressive type, such as mantle cell lymphoma [41].
However, because of their indolent, localized clinical pre-
sentation, diagnosis is often accompanied by substantial
difficulty, with the majority of cases being diagnosed inci-
dentally. Admitted that even in case of lymphoma, there
is a certain chance of cure by means of medical treatment
without surgery, en bloc resection of the hepatic tumor
would be recommended as a principle procedure for sub-
sequent diagnosis and decision for treatment. Needle
biopsy failed to present a diagnosis in our case, partly
because the tumor was among the smallest of the
reported cases in the literatures. Finally, in such situation,
laparoscopic approach would provide a reasonable proce-
dure of less invasiveness for patients [42].
Conclusion
HPL and MALT lymphoma are very rare. We herein
report a case with a space occupying lesion in the left
lateral segment of the liver, which was completely
resected by laparoscopic-assisted lateral segmentect-
omy. The tumor of maximal 1.0 cm in diameter was
consisted of aggregation of lymphocytes of predomi-
nantly B-cell, containing multiple lymphocyte follicles
positive for CD10 and bcl-2, consistent with a diagno-
sis of HPL, but still necessitating differential diagnosis
from MALT lymphoma. Since the accurate diagnosis
of this entity is difficult, laparoscopic approach would
provide a reasonable procedure of diagnostic and ther-
apeutic advantage with minimal invasiveness for
patients. Considering that the real nature of this entity
remains unclear to date, vigilant follow-up of patient is
essential.
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